<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692884</url>
  </required_header>
  <id_info>
    <org_study_id>CDR2018</org_study_id>
    <nct_id>NCT03692884</nct_id>
  </id_info>
  <brief_title>Chongqing Diabetes Registry Study</brief_title>
  <acronym>CDR</acronym>
  <official_title>Chongqing Diabetes and Its Chronic Complications Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the risk factors and biomarkers of the microvascular disease，macrovascular
      disease and neuropathy in patients with diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective cohort study. About 5000 patients with diabetes from the
      Chongqing Diabetes Centre,Chongqing,China, will be enrolled for long-term
      follow-up.Information on socio-demographic parameters, medical history, current drug
      use,lifestyle factors, anthropometric measurements, metabolic control indicators and diabetes
      complications examination will be documented. Blood and urine samples will be collected. This
      study aimed to assess risk factors and biomarkers of occurrence and development of diabetic
      microvascular disease,macrovascular disease and neuropathy in patients with diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>The number of patients whoes Diabetic Kidney disease (DKD) is worsen</measure>
    <time_frame>5 years</time_frame>
    <description>Worsen DKD is defined as Urine Albumin Creatinine Ratio （UACR）&gt; 300 mg/g Cr（twice out of three measures）, or 24 hours urinary protein&gt; 300 mg / 24 h, or double serum creatinine level and at least 200μmol/l (2.26 mg/dl), or require renal replacement therapy, or death due to kidney disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients who develop DKD</measure>
    <time_frame>5 years</time_frame>
    <description>Diabetic Kidney Disease is defined as UACR &gt; 30 mg/g Cr（twice out of three measures），or estimated Glomerular Filtration Rate（eGFR）＜60ml/min/1.73m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who develop Diabetic Retinopathy</measure>
    <time_frame>5 years</time_frame>
    <description>New Diabetic Retinopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients whoes DR is worsen</measure>
    <time_frame>5 years</time_frame>
    <description>Worsen DKD is defined as any eye with original Diabetic Rretinopathy aggravated by at least one level, or progress to proliferation retinopathy, or appearance of macular degeneration, or at least one eye with blindness (refer to the WHO standards, the Snellen-chart vision drop to 6/60 or less), or to accept retinal photocoagulation treatment, or accept vitrectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who develop Diabetic Neuropathy</measure>
    <time_frame>5 years</time_frame>
    <description>Diabetic Peripheral Neuropathy is defined as Neuropathy Symptom Score/Neuropathy Disability Score（NSS/NDS） with at least two positive outcomes, or electromyography examination to identify nerve damage；Diabetic Autonomic Neuropathy is defined as tachycardia at rest (Heart Ratio&gt;100bpm) and postural hypotension (standing position leads systolic blood pressure reduction &gt;20mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who develop Cardiovascular events</measure>
    <time_frame>10 years</time_frame>
    <description>Cardiovascular events are difined as death of cardiovascular events, or non-fatal myocardial infarction, or non-fatal stroke, or revascularization procedure (cardiac, carotid, or peripheral), or hospitalization for heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who develop Diabetic foot</measure>
    <time_frame>10 years</time_frame>
    <description>Diabetic foot was defined as active diabetic foot problem: ulceration, spreading infection, critical ischaemia, gangrene, suspicion of an acute Charcot arthropathy, or an unexplained hot, red, swollen foot with or without pain.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Diabetes Mellitus</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma,complete blood cell and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects who diagnosed of diabetes mellitus and signed on the informed consent will be
        enrolled in our study. We intend to enroll hospitalized patients or outpatient with
        diabetes mellitus from Chongqing Diabetes Centre,Chongqing,China.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of diabetes mellitus（based on the 1999 WHO diagnostic cretirial）;

          2. Age younger than 75 years old, gender is not limited;

          3. Voluntary to sign on the informed consent.

        Exclusion Criteria:

          1. pregnant or breast-feeding women;

          2. Patients with chronic disease requiring long-term glucocorticoid therapy;

          3. Patients with severe infection (except for diabetic foot) or immune dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, phD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifu Li, phD</last_name>
    <phone>+86 023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhihong Wang, phD</last_name>
    <phone>+86 023-89011552</phone>
    <email>towzh713@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qifu Li</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, PhD</last_name>
      <phone>+86 23 89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
    <investigator>
      <last_name>Zhihong Wang, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingfeng Cheng, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shumin Yang, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinbo Hu, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yue Wang, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lilin Gong, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>October 7, 2018</last_update_submitted>
  <last_update_submitted_qc>October 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Director of endocrinology</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>risk factors</keyword>
  <keyword>biomarkers</keyword>
  <keyword>chronic diabetes complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

